Fallopian tube (FT) and endometrial urocortin 1 (Ucn1) and corticotropin-releasing hormone (CRH)-receptor (CRH-R1/CRH-R2) expression were examined using quantitative real-time polymerase chain reaction (RT-PCR) and immunohistochemistry in nonpregnant and pregnant women (intrauterine, IUP; ectopic pregnancy, EP). Tubal Ucn1 messenger RNA (mRNA) expression was higher in luteal compared to follicular phase (P < .01) and equivalent to follicular phase in FT from EP. Tubal CRH-R1/CRH-R2 mRNA was lower in luteal phase (P < .05) and in FT from EP compared to follicular phase (P < .01). Ucn1 mRNA was lower in endometrium from EP compared to IUP (P < .05). Corticotropin-releasing hormone-R1 mRNA was higher in endometrium from EP compared to viable IUP (P < .05). No differences were observed in CRH-R2 expression. Corticotropin-releasing hormone-R1 protein was primarily localized to epithelium of FT and endometrium. Quantitative analysis of tubal CRH-R1 protein expression reflected that seen at the mRNA level but endometrial expression was equivocal. The demonstration of attenuated tubal/endometrial Ucn1/CRH-R expression in EP further supports a role of the CRH-family in embryo implantation.
Introduction
Tubal ectopic pregnancy remains a common cause of morbidity and occasional mortality. 1 In the United Kingdom, between 2003 and 2005, early pregnancy bleeding was the third commonest cause of maternal death and more than 60% of these cases were due to ruptured tubal ectopic pregnancies. 2 In the United States, ruptured tubal ectopic pregnancy remains the commonest cause of pregnancy-related first trimester death. 3 In the developing world, the incidence of ectopic pregnancy is much higher and 1 in 10 women admitted with a diagnosis of ectopic pregnancy ultimately die from the condition. 4 Despite advances in our understanding of intrauterine implantation and early pregnancy, our knowledge of the complex molecular and cellular interactions that contribute to tubal implantation is limited. 5 The corticotropin-releasing hormone (CRH) family includes a variety of neuropeptides, including urocortin 1 (Ucn1), and the CRH receptors (types 1 and 2; CRH-R1 and CRH-R2). 6 Urocortin 1, a 40 amino acid peptide, is closely related to CRH, 7 not only in sequence homology but also because it binds both CRH receptors with high affinity. 8, 9 Urocortin 1 is known to play a significant role in the physiology of human reproduction, including steroidogenesis, myometrial contractility, and the initiation of labour. 6, 10, 11 Urocortin 1 and the CRH receptors are also thought to play an important part in endometrial decidualization and successful intrauterine implantation. 6, 10 Urocortin 1 is expressed in the endometrial epithelial and stromal cells throughout the menstrual cycle, 12 with the highest expression observed in the secretory phase. 13 It induces endometrial cell decidualization even in the absence of sex steroid hormones and is also secreted by the stroma during decidualization, modulating the maternal response to the invading trophoblast. 13 Urocortin 1 is highly expressed by human extravillous trophoblast cells (EVT; the invasive part of the placenta) 14 and it has been reported to have a potent vasodilator action on the placental bed. 15 Furthermore, higher Ucn1 levels have been observed in endometrial flushings from women who achieved pregnancy after intrauterine insemination compared to those who did not, suggesting that Ucn1 may only be secreted in appreciable amounts by a receptive endometrium. 16 Both CRH-R1 and CRH-R2 17, 18 are also expressed in the human endometrium throughout the menstrual cycle, but only CRH-R1 is expressed on EVT cells. 19 Corticotropin-releasing hormone-R2 is extensively expressed in vascular tissues, 20, 21 and its action on vascular tone control promotes vasodilation. 22, 23 Recent studies have shown that, in the human endometrium, CRH-R1 antagonists have the potential to be used as abortive agents (blockage of CRH-R1 in rats decreases implantation in rats in a dose-dependent way). 19, 24 It has been also suggested that CRH-R1 takes part in the control of trophoblast invasion and embryo-maternal immunotolerance by killing activated T cells expressing the Fas membrane protein at the fetalmaternal interface, an effect completely reversed by antalarmin, a specific CRH-R1 antagonist. 19 We believe that ectopic implantation in the Fallopian tube (FT) is manifest by an alteration in Ucn1 and CRH receptor expression reflecting pathological embryo invasion. We hypothesised that Ucn1 and CRH receptor mRNA expression in the nonpregnant FT would be similar to that observed in the endometrium but different at tubal implantation sites and in the decidualized endometrium of women with tubal ectopic compared to intrauterine pregnancies.
Material and Methods

Tissue Collection
Ethical approval for this study was obtained from the Lothian Research Ethics Committee (LREC 04/S1103/20), and informed written consent was obtained from all study participants. Timed FT biopsies (all full-thickness from ampullary region) were obtained from healthy fertile women (age 19-40 years) with regular menstrual cycles (21-35 days) undergoing surgery for benign gynecological conditions (eg, heavy menstrual bleeding, adenomyosis; n ¼ 12; Table 1 ). Dating of the samples was ascertained by consistency of circulating serum estradiol and progesterone levels and histological analysis of an endometrial biopsy at time of sample collection (using Noyes' criteria). Fallopian tube was also collected from women undergoing surgery for tubal ectopic pregnancy (n ¼ 6). Decidualized endometrium was obtained from women (age 19-40 years) undergoing surgical termination of pregnancy (viable intrauterine; n ¼ 10, mean gestation 67.4 days); surgical management of embryonic missed miscarriage (nonviable intrauterine; n ¼ 7, mean gestation 71.3 days), and surgical management of tubal ectopic pregnancy (n ¼ 12, mean gestation 58.1 days). None of the pregnant women had undergone in vitro fertilization and none of the women undergoing surgical management of tubal ectopic pregnancy presented acutely with hemodynamic shock, and all required serial serum b-human chorionic gonadotropin (hCG) and ultrasound monitoring before diagnosis. None of the participants had received medication (eg, hormones or prostaglandins) in the 5 days leading up to the procedure or had an intra-uterine contraceptive device in-situ. The decidualized endometrium and trophoblast were obtained by suction curettage from the women with intrauterine pregnancies and by Pipelle (Eurosurgical Ltd, Cranleigh) from the women with tubal ectopic pregnancies. The decidualized endometrium was isolated from the trophoblast macroscopically. Hematoxylin and eosin staining and immunohistochemistry for cytokeratin demonstrated clear isolation of the decidualized endometrium from the trophoblast as described previously. 25 Samples were either immersed in RNA later (Ambion, Inc, Austin, Texas) at 4 C overnight and flash frozen at -80 C for RNA extraction or immersed in 4% neutral buffered formalin for 24 hours then transferred into 70% ethanol and paraffin embedded for immunohistochemistry.
RNA Extraction
Total RNA was extracted from all samples as detailed in the manufacturers' protocol (Qiagen, West Sussex). The concentration and quality of the extracted RNA was assessed using an Agilent bioanalyser and quantified using an ND-1000 spectrophotometer (Nanodrop Technologies, Delaware). All samples were standardized for quality control and assigned an RNA integrity number (RIN). RNA samples were considered to be of good quality when a mean RIN value of 7.5 was obtained. 26 Quantitative RT-PCR After DNAse treatment, using RQ1 DNase (Promega, Southampton), the RNA was reverse transcribed into complementary DNA (cDNA) using random hexamers (Applied Biosystems, Foster City, California). TaqMan quantitative RT-PCR was then performed using Applied Biosystems' inventoried TaqMan Gene Expression Assay for the following genes: human urocortin 1 (Ucn1; Hs00175020_m1), human CRH receptor type 1 (CRH-R1; Hs01062290_m1), and human CRH Mid luteal 331 83. 5 10 Mid luteal 424 76. 9 11 Mid luteal 1633 54. 38 12 Mid luteal 266 37.1 receptor type 2 (CRH-R2; Hs00266401_m1). All sample reactions were performed in triplicate and a relative comparison was made to a control tissue cDNA which was included in all reactions. Using the 2DDCt method, Ucn1, CRH-R1, and CRH-R2 mRNA expression results were normalized against ribosomal 18S internal control (Applied Biosystems) and expressed as the fold change when compared with the control group.
Serum Assays
Serum progesterone and hCG concentrations were measured using a standard radioimmunoassay. 27 Levels were correlated to tissue mRNA levels of each gene using Excel.
Immunohistochemistry
Immunohistochemical localization of CRH-R1 was performed using a goat polyclonal antibody (Santa Cruz Biotechnology, Wembly, UK), biotinylated secondary antibody, and peroxidase conjugated detection. Immunoreactivity was visualized using the chromagen 3,3 0 -diaminobenzidine (DAB). Tissue sections were dewaxed in xylene and rehydrated in descending grades of alcohol. Sections were subjected to antigen retrieval in 0.01 mol/L sodium citrate and nonspecific activity was blocked sequentially with 3% hydrogen peroxide (Sigma-Aldrich, Poole, UK), avidin, biotin, and protein blocks. Sections were incubated overnight at 4 C with primary antibody. Sections were subsequently incubated with biotinylated secondary antibody (Vector Laboratories, Peterborough) and HRP complex (ABC-Elite, Vector Laboratories) then immunoreactivity detected using DAB (Vector Laboratories). Counterstaining was then performed with Harris' hematoxylin and mounted in Pertex (Cellpath Technologies, Hemel Hempstead). Negative controls were included where the primary antibody was preincubated with a blocking peptide (Santa Cruz Biotechnology) and third trimester placenta was used as a positive control.
Scoring
For assessment of CRH-R1 immunostaining in FT and endometrium, a histoscore was applied by 2 independent observers as previously described. 28 A separate histoscore was applied to surface epithelium and stroma where appropriate.
Statistical Analysis
All data were assessed for normality of distribution using a computer programme (Prism 4; Graphpad Software, California). Where the data were normally distributed, and 3 or more groups were being analyzed, an analysis of variance (ANOVA) with Tukey multiple comparison test was used. Where only 2 groups were being analyzed, a t test was used. A chi-square test was used to compare proportions. Spearman (nonparametric) coefficients were used to assess linear correlations. Histoscoring was analyzed using the Kruskal-Wallis test assuming a non-Gaussian distribution. P < .05 was taken to indicate statistical significance.
Results
Urocortin 1 mRNA Expression in Nonpregnant Human FT and in FT From Women With Ectopic Pregnancy
In the nonpregnant human FT, Ucn1 mRNA expression was higher in the progesterone-dominant luteal phase (mean DCT 14.76 + SEM 0.35, n ¼ 8) compared to the follicular phase (16.44 + 0.25, n ¼ 4; P < .01; Figure 1 ). In FT from women with ectopic pregnancy (where tubal implantation had occurred), Ucn1 mRNA expression was similar to that observed in the follicular phase (16.70 + 0.43, n ¼ 6; Figure 1 ).
Corticotropin-Releasing Hormone Receptor (Types 1 and 2) mRNA Expression in Nonpregnant Human FT and in FT From Women With Ectopic Pregnancy
Both CRH receptors (types 1 and 2) assumed the same pattern of expression in the nonpregnant FT and in FT from women with ectopic pregnancy. viable intrauterine and ectopic pregnancy (Figure 3) . The findings could not be explained by differences in gestational age.
Corticotropin-Releasing Hormone Receptor (Types 1 and 2) mRNA Expression in Decidualized Endometrium From Women With Intrauterine and Ectopic Pregnancy
Corticotropin-releasing hormone-R1 mRNA expression was significantly higher in decidualized endometrium from ectopic (17.36 + 0.87, n ¼ 12) compared to viable intrauterine pregnancy (20.84 + 0.43, n ¼ 10; P < .05). No significant difference in expression was observed when compared to decidualized endometrium from nonviable intrauterine pregnancy ( Figure 4 ). Corticotropin-releasing hormone receptor type 2 mRNA expression was not significantly different in the decidualized endometrium from the 3 groups analyzed, but there was a nonsignificant trend for lower expression in the nonviable pregnancy group (Figure 4) . The findings were correlated with gestation (days) but could not be explained by differences in gestational age within the study population.
Corticotropin-Releasing Hormone-R1 Protein Expression in FT and Decidualized Endometrium
Corticotropin-releasing hormone-R1 protein was localized to the epithelium of the FT (Figure 5a-c) . Expression was cytoplasmic with nuclear sparing. There was no difference in localization at different times of the menstrual cycle or in FT from women with ectopic pregnancy. Corticotropin-releasing hormone-R1 showed a similar pattern of expression in the decidualized endometrium although there was evidence of patchy cytoplasmic stromal expression ( Figure 5d-f ). There was no difference in localization in the ectopic pregnancy compared to the intrauterine groups. Corticotropin-releasing hormone-R1 protein expression was quantified by applying a histoscore (0-300; Figure 6a -c). None of the differences between each group were statistically significant. However, tubal epithelial CRH-R1 expression showed a nonsignificant trend reflecting CRH-R1 expression at the mRNA level. Expression was higher in the follicular compared to the luteal phase and lower than the luteal phase in FT from women with ectopic pregnancy (where tubal implantation had occurred).
Correlation of Decidual Urocortin and CRH-R1 mRNA Expression With Serum Progesterone and hCG Concentrations
Human chorionic gonadotropin and progesterone levels were measured in all patients with a viable intrauterine and ectopic 
Discussion
To our knowledge, this is the first description of Ucn1 and CRH receptor mRNA expression in the nonpregnant human FT at different stages of the menstrual cycle and in women with ectopic pregnancy. Furthermore, we also compare the expression of Ucn1 and CRH receptor mRNA in the decidualized endometrium of women with intrauterine compared to ectopic pregnancies. Similar to human endometrium, 13 we demonstrate that tubal Ucn1 mRNA expression is higher in the progesteronedominant luteal compared to both the follicular phase. We also show that tubal expression in the luteal phase is higher than that observed in FT from women with ectopic pregnancy where tubal implantation has occurred. The latter data may be due to the fact that tubal decidualization is not generally observed in ectopic pregnancy. 29, 30 Urocortin 1 is highly expressed in the secretory endometrium 13 and in EVT cells,14 promotes decidualization in-vitro, 13 and is only produced in large amounts by an endometrium receptive to a presenting embryo. 16 In addition, we show that CRH-R1 and CRH-R2 mRNAs are expressed in nonpregnant FT with statistically lower expression in the luteal compared to the follicular phase. Tubal CRH-R1 protein expression showed a similar nonstatistically significant trend. In the endometrium, the CRH receptors are expressed throughout the menstrual cycle but cyclical variations have not been reported. 18 Since CRH-R1 promotes implantation through an inflammatory-like reaction of the endometrium, 19 and CRH-R2 promotes vasodilation within the placental bed, 22,23 the reduced expression observed in the FT during the luteal phase may in theory act as a barrier to unwanted ectopic implantation.
Furthermore, we demonstrate that CRH-R1 and CRH-R2 mRNA expression in FT from women with ectopic pregnancy is also lower than that observed in the follicular but equivalent to that seen in the luteal phase. We also demonstrate a similar but nonsignificant trend in CRH-R1 protein expression. Pregnancies with abnormal placental function and vascular resistance are characterized by reduced CRH-R1 expression. 31 Corticotropin-releasing hormone treatment, mediated by CRH-R1, causes a reduction in the expression of adhesion molecules and EVT invasion in vitro, 32 and antalarmin, a CRH-R1-specific antagonist, increases EVT invasion in Matrigel assays allowing an uncontrolled trophoblast invasion. 14 Moreover, CRH-R2 is expressed in the uterine vascular bed 20, 21 and modulates angiogenesis by inhibiting neovascularization in vitro. 33 Therefore, we propose that the low CRH-R1 and CRH-R2 mRNA expression observed at the tubal implantation sites may contribute to the chaotic trophoblast invasion and aberrant vascularisation associated with ectopic pregnancy.
We also showed that Ucn1 mRNA expression is lower in decidualized endometrium from women with an ectopic compared to a normal intrauterine pregnancy. A recent study showed that Ucn1 levels are directly related to the degree of decidualization of the endometrium 13 and a direct correlation between Ucn1 concentrations in endometrial flushings and successful implantation has been reported. 16 Additionally, locally produced CRH, which shares 45% homology with Ucn1 7 and acts with lower affinity than Ucn1 through the same receptors, 8, 9 has been reported to promote implantation and maintenance of early pregnancy, primarily by inducing apoptosis in activated T cells at the maternal-fetal interface, allowing Corticotropin-releasing hormone receptor type 1 mRNA expression was higher in decidualized endometrium from patients with ectopic compared to viable intrauterine pregnancy (*P < .05). No difference in CRH receptor type 1 expression was observed between nonviable and ectopic pregnancy. No difference in CRH receptor mRNA expression was observed in the 3 groups analyzed. TOP indicates termination of pregnancy (viable intrauterine pregnancy); misc ¼ miscarriage (nonviable intrauterine pregnancy); ectopic ¼ ectopic pregnancy. Data are mean +SEM.
controlled trophoblast invasion and implantation into maternal deciduas. 19 Thus, it is likely that a pregnancy implanted in FT has abnormal growth kinetics that are reflected in impaired trophoblast function. Markers of luteal, trophoblast, and decidual function are altered in ectopic pregnancy. [34] [35] [36] [37] This study confirms an alteration in endometrial secretory function in ectopic pregnancy, possibly due to an absence of trophoblastderived Ucn1 at the fetal-maternal interface. We are aware that we have only documented statistically significant changes at an mRNA level and that these changes may not necessarily be reflected as alterations in protein expression. We found that CRH-R1 mRNA expression is considerably higher in the decidualized endometrium of patients with ectopic compared to viable intrauterine pregnancies. Corticotropinreleasing hormone-R1 is the only CRH receptor detected in EVT cells and CRH-R1 blockade by antalarmin prevents implantation in rats by reducing the inflammatory-like reaction of the endometrium to the invading blastocyst. 19 The maternal endometrial response to the invading semiallograft embryo has the characteristics of an acute inflammatory response and, once implanted, the embryo suppresses this response and prevents its rejection. As CRH-R1 has a proinflammatory effect in a number of tissues 38, 39 and is considered necessary for successful implantation by promoting early embryo-maternal tolerance, 19 the increased decidual CRH-R1 mRNA levels observed in ectopic pregnancy may be due to the absence of intrauterine trophoblast, responsible for the antirejection process that protects the fetus from maternal immune system. Alternatively, as it may be assumed that the genetic make-up of the EVT cells is similar in intrauterine and ectopic pregnancies, a proinflammatory intrauterine environment leading to abnormal maternal immune tolerance to the fetal semiallograft and vice versa may contribute to an environment that is not conducive to normal intrauterine implantation and lead to ectopic trophoblast invasion.
This finding was not reflected at the protein level, possibly reflecting a degree of variation in the immunohistochemical scoring system and would benefit from quantification by Western blot analysis on isolated epithelial and stromal epithelial cells.
No correlation was observed between Ucn1 mRNA, or CRH-R1 mRNA, and serum progesterone or hCG levels in patients, suggesting that other pathways are involved in the control of Ucn 1/CRH receptor type 1 expression in decidualized endometrium.
In conclusion, this study has demonstrated that (1) Ucn1 and CRH receptor mRNAs are expressed in the FT across the menstrual cycle, complementing data on their expression pattern in the endometrium; (2) Ucn 1 and CRH receptor mRNA expression is low in the FT of women with ectopic pregnancy where tubal implantation has occurred, attributed to deficient tubal decidualization with ectopic pregnancy; (3) there is a likely imbalance between CRH-R1 and its ligand in the decidualized endometrium of women with ectopic pregnancy, supporting an important role of the CRH family in endometrial differentiation Figure 6 . Quantification of Corticotropin-releasing hormone-receptor 1 (CRH-R1) protein expression in Fallopian tube and decidualized endometrium. Corticotropin-releasing hormone-receptor 1 protein expression was quantified (n ¼ 5) by applying a histoscore (0-300) and presented as box and whisker plots (median and range). None of the differences between each group were statistically significant. However, tubal epithelial CRH-R1 expression showed a nonsignificant trend reflecting CRH-R1 expression at the messenger RNA (mRNA) level. TOP indicates viable intrauterine pregnancy; misc ¼ nonviable intrauterine pregnancy; EP ¼ ectopic pregnancy.
